A one-per-day pill that targets cancer-causing mutations has been shown in a recent trial to decrease the risk of death by 57 percent in patients with a particularly tough late-stage leukemia.

Called Imbruvica, the pill is already approved by the Food and Drug Administration for use against a different blood cancer called mantle cell lymphoma, as well as for chronic lymphocytic leukemia.

(READ the full story from TODAY)

Leave a Reply